StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Price Performance
NASDAQ AKTX opened at $0.16 on Friday. Akari Therapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $1.61. The stock has a market cap of $12.01 million, a price-to-earnings ratio of -0.46 and a beta of 1.31. The business has a fifty day moving average of $0.18 and a 200-day moving average of $0.32.
Institutional Trading of Akari Therapeutics
A number of institutional investors have recently modified their holdings of AKTX. LPL Financial LLC purchased a new stake in Akari Therapeutics during the 2nd quarter worth approximately $83,000. Renaissance Technologies LLC boosted its holdings in shares of Akari Therapeutics by 411.4% during the first quarter. Renaissance Technologies LLC now owns 283,550 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 228,100 shares during the period. Finally, Sabby Management LLC increased its holdings in shares of Akari Therapeutics by 116.5% during the first quarter. Sabby Management LLC now owns 7,941,867 shares of the biopharmaceutical company’s stock valued at $1,443,000 after purchasing an additional 4,273,528 shares during the period. Hedge funds and other institutional investors own 13.60% of the company’s stock.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
See Also
- Get a free research report on Akari Therapeutics from StockNews.com
- MarketBeat Week in Review – 6/19 – 6/23
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Five stocks we like better than Akari Therapeutics
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
